McKoy M G, Kong-Quee Iii P, Pepple D J
Department of Basic Medical Sciences (Pharmacology Sections), The University of the West Indies, Mona Campus, Kingston, Jamaica, W.I.
Department of Basic Medical Sciences (Physiology Sections), The University of the West Indies, Mona Campus, Kingston, Jamaica, W.I.
Indian J Med Res. 2016 May;143(5):577-80. doi: 10.4103/0971-5916.187105.
BACKGROUND & OBJECTIVES: The antimalarial combination drug artemether/lumefantrine has been shown to be effective against malaria parasite through its haemolytic action. This drug is sometimes co-administered with vitamin C in patients with malaria. Vitamin C is associated with antioxidant properties which would be expected to protect against haemolytic effects of this antimalarial drug. This study was designed to investigate in vitro effects of co-incubation of artemether/lumefantrine with vitamin C on the viscosity and elasticity of blood.
Blood was collected from 12 healthy female volunteers with normal haemoglobin genotype (HbAA). A Bioprofiler was used to measure the viscosity and elasticity of untreated blood samples (control) and samples exposed to artemether/lumefantrine (0.06/0.36 mg/ml) alone and with low or high dose vitamin C (equivalent to adult doses of 100 or 500 mg).
artemether/lumefantrine significantly (p<0.05) reduced viscosity of blood from 4.72 ± 0.38 to 3.78 ± 0.17 mPa.s. Addition of vitamin C (500 mg) further reduced blood viscosity to 2.67 ± 0.05 mPa.s. The elasticity of blood was significantly (p<0.05) reduced from 0.33 ± 0.04 mPa.s to 0.24 ± 0.03 mPa.s by the antimalarial drug, and further reduced to 0.13 ± 0.02 mPa.s in the presence of vitamin C (500 mg).
INTERPRETATION & CONCLUSIONS: Co-incubation of blood with vitamin C and antimalarial combination drug potentiates the haemolytic effects of the latter on reducing blood viscosity and elasticity in vitro. This may possibly have implications in relation to haemolysis in patients receiving vitamin C supplementation with artemether/lumefantrine during malaria therapy.
抗疟复方药物蒿甲醚/本芴醇已被证明可通过其溶血作用有效对抗疟原虫。在疟疾患者中，这种药物有时会与维生素C联合使用。维生素C具有抗氧化特性，有望预防这种抗疟药物的溶血作用。本研究旨在调查蒿甲醚/本芴醇与维生素C共同孵育对血液粘度和弹性的体外影响。
从12名血红蛋白基因型正常（HbAA）的健康女性志愿者采集血液。使用生物分析仪测量未处理血液样本（对照）以及单独暴露于蒿甲醚/本芴醇（0.06/0.36 mg/ml）和低剂量或高剂量维生素C（相当于成人剂量100或500 mg）的样本的粘度和弹性。
蒿甲醚/本芴醇显著（p<0.05）降低血液粘度，从4.72±0.38降至3.78±0.17 mPa·s。添加维生素C（500 mg）进一步将血液粘度降低至2.67±0.05 mPa·s。抗疟药物使血液弹性显著（p<0.05）从0.33±0.04 mPa·s降至0.24±0.03 mPa·s，在维生素C（500 mg）存在的情况下进一步降至0.13±0.02 mPa·s。
血液与维生素C和抗疟复方药物共同孵育可增强后者在体外降低血液粘度和弹性的溶血作用。这可能对疟疾治疗期间接受维生素C补充剂与蒿甲醚/本芴醇联合治疗的患者的溶血情况有影响。
